Uncategorized

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) – July 20, 2023

Schrödinger, Inc. today reported that on July 14, 2023, the company granted (i) non-statutory stock options to purchase 10,250 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 6,225 shares of the company’s common stock to nine newly hired employees.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) – July 20, 2023 Read More »

Rarecells, Inc. announces a breakthrough publication on Circulating Giant Cancer Cells detected in patients with MDS

Rarecells is thrilled to announce its breakthrough publication, written in partnership with the team of Dr. Azra Raza from Columbia University Irving Medical Center, revealing for the first time the presence of circulating giant cancer cells (CGCCs) in patients with Myelodysplastic Syndrome (MDS).

Rarecells, Inc. announces a breakthrough publication on Circulating Giant Cancer Cells detected in patients with MDS Read More »

Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023

Karuna Therapeutics, Inc. announced that it will host a live conference call and webcast on Thursday, August 3, 2023 at 8:00 a.m. ET to review second quarter 2023 financial results and provide a general business update.

Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023 Read More »

Scroll to Top